Shire: The Leading Global Biotech Focused on Rare Diseases

• http://www.shire.at/
• http://www.shiredanmark.dk/
• http://www.shire.fr
• http://www.shire.de/
• http://www.shire.ie
• http://www.shireitalia.it/
• http://www.shire.nl/
• http://www.shirenorge.no/
• http://www.shire.pt/
• http://www.shireiberica.com/
• http://www.shiresverige.se/
• http://www.shireswitzerland.ch/
• http://www.shireswitzerland.ch/fr-ch
• http://www.shireturkey.com
• http://www.shirepharmaceuticals.co.uk/
• http://www.shireargentina.com.ar/
• http://www.shire.com.br/
• http://www.shirecanada.com/en
• http://www.shirecanada.com/fr
• http://www.shire.com.co/
• http://www.shire.com.mx/
• http://www.shireaustralia.com.au/
• http://www.shire.com.cn
• http://www.shire.co.jp/
• http://www.shire.co.kr/
• https://www.shire.com/en
• http://investors.shire.com/?_ga=1.45997668.1594314063.1451576827
• http://investors.shire.com/our-strategy.aspx?_ga=1.75813461.1594314063.1451576827
• http://investors.shire.com/shareholder-resources/shareholder-information.aspx
• http://investors.shire.com/financial-information/financial-highlights.aspx
• http://investors.shire.com/dividend-information/dividends-policy.aspx
• http://investors.shire.com/debt-investors.aspx
• http://investors.shire.com/shareholder-resources/annual-general-meeting.aspx
• http://investors.shire.com/recent-acquisitions/baxalta-acquisition.aspx
• http://investors.shire.com/recent-acquisitions/proposed-dyax-corp-acquisition.aspx
• http://investors.shire.com/recent-acquisitions/nps-pharma-acquisition.aspx
• http://investors.shire.com/presentations-and-reports/quarterly-results-and-presentations/year-2018.aspx
• http://investors.shire.com/presentations-and-reports/annual-and-interim-reports/year-2018.aspx
• http://investors.shire.com/presentations-and-reports/conflict-minerals-disclosure.aspx
• http://investors.shire.com/takeda
• http://investors.shire.com/investor-news.aspx?_ga=1.13948919.1594314063.1451576827
• http://investors.shire.com/news-and-events/events-calendar.aspx
• https://www.shire.com/newsroom
• https://www.shire.com/newsroom#content_0_rowcontainer_1_pagecontentleftsecondary_0_Headline
• https://www.shire.com/newsroom/social-media
• https://www.shire.com/contact-us
• https://www.shire.com/
• https://www.shire.com/newsroom#content_0_rowcontainer_1_pagecontentleftsecondary_0_PageEditorMessage
• http://investors.shire.com
• http://investors.shire.com/analysts.aspx
• http://investors.shire.com/presentations-and-reports/annual-and-interim-reports/year-2017.aspx
• http://investors.shire.com/events-calendar.aspx
• http://investors.shire.com/financial-highlights.aspx
• http://investors.shire.com/investor-news.aspx
• http://investors.shire.com/our-strategy.aspx
• http://investors.shire.com/disclaimer-baxalta-acquisition.aspx
• http://investors.shire.com/shareholder-information.aspx
• https://www.shire.com/who-we-are
• https://www.shire.com/who-we-are/areas-of-focus
• https://www.shire.com/who-we-are/areas-of-focus/neuroscience
• https://www.shire.com/who-we-are/areas-of-focus/genetic-diseases
• https://www.shire.com/who-we-are/areas-of-focus/hematology
• https://www.shire.com/who-we-are/areas-of-focus/immunology
• https://www.shire.com/who-we-are/areas-of-focus/internal-medicine
• https://www.shire.com/who-we-are/areas-of-focus/ophthalmics
• https://www.takeda.com/corporate-responsibility/
• https://www.takeda.com/who-we-are/company-information/executive-leadership/
• https://www.shire.com/who-we-are/how-we-operate
• https://www.shire.com/who-we-are/how-we-operate/partnerships
• https://www.shire.com/who-we-are/how-we-operate/policies-and-positions
• https://www.shire.com/who-we-are/how-we-operate/transparency-disclosures
• https://www.shire.com/who-we-are/how-we-operate/policies-and-positions/supplier-information
• https://www.shire.com/patients
• https://www.shire.com/patients/patient-resources
• https://www.shire.com/patients/patient-services
• https://www.shire.com/patients/patient-services/onepath
• https://www.shire.com/patients/patient-services/shire-cares
• https://www.shire.com/patients/patient-services/hematology-support
• https://www.shire.com/patients/patient-advocacy
• https://www.shire.com/patients/patient-advocacy/about-patient-advocacy
• https://www.shire.com/patients/patient-advocacy/working-together
• https://www.shire.com/patients/charitable-access-program
• https://www.shire.com/patients/scholarships
• https://www.shire.com/research-and-development
• https://www.takeda.com/what-we-do/research-and-development/
• https://www.shire.com/research-and-development/educational-grants
• https://www.shire.com/research-and-development/investigator-initiated-research
• https://www.shire.com/research-and-development/collaborative-research
• https://www.takeda.com/what-we-do/research-and-development/our-pipeline/
• https://www.shire.com/research-and-development/clinical-trials
• https://www.shire.com/research-and-development/collaborations
• https://www.shire.com/products
• https://www.shire.com/products/product-list
• https://www.shire.com/products/manufacturing
• https://www.shire.com/products/manufacturing/our-principles
• https://www.shire.com/products/manufacturing/product-safety
• https://www.shire.com/products/postmarketing-commitments
• https://www.takedajobs.com/
• https://www.shire.com/newsroom/2019/january/takeda-completes-acquisition
• https://www.takeda.com/terms-of-use/
• https://www.shire.com/legal-notice/privacy-notice
• https://www.takeda.com/investors/
• https://www.shire.com/legal-notice/product-patents
• https://www.takeda.com/en-gb/modern-slavery-act-transparency-statement/
• https://www.shire.com/newsroom/rss-feed
• https://www.shire.com/contact-us/website-feedback
• http://www.shire.com
• https://twitter.com/TakedaPharma
• https://www.linkedin.com/company/takeda-pharmaceuticals/
• https://www.youtube.com/c/shireplc